Clinical Observation Of Different Dosages Of Nab-paclitaxel In The Treatment Of Advanced Non-small Cell Lung Cancer With Negative Driver Gene

Objective:By observing the different dosage of Nab-Paclitaxel treated drive gene negative and advanced non-small cell lung cancer patients（NSCLC）with curative effect and adverse reaction,to explore suitable scheme of Nab-Paclitaxel for drive gene negative patients with NSCLC,provide the basis for clinical doses of choice.Method:From January 2020 to July 2021,64 patients of advanced NSCLC with negative driver gene in Inner Mongolia General Forestry Hospital were collocted.Patients were divided into experimental group（n=30 cases）and control group（n=34 cases）according to their condition and willingness.The experimental group received cisplatin/carboplatin and Nab-Paclitaxel 130mg/m²by intravenous infusion on 1^stand 8^thdays,21 days as a cycle of chemotherapy.The other group as control group received cisplatin/carboplatin and Nab-Paclitaxel 260mg/m²by intravenous infusion on 1^st,21 days as a cycle of chemotherapy.Efficacy and adverse reactions were evaluated after 2 and 1cycles,respectively.Finally analyzed the objective response rate（ORR）and adverse reactions in 2 groups.Result:Among the 64 patients,control group had 2 cases out,and there were 62 cases of curative effects and adverse reactions.1.Objective response rate ORR（CR+PR）:the ORR of experimental group and control group were 26.7%and 28.1%（P>0.05）,and disease control rate DCR（CR+PR+SD）:The DCR were 73.3%and 71.9%（P>0.05）,and the median progression-free survival（PFS）was 6.8 and 4.2 months,respectively（P>0.05）.2.Adverse reactions:adverse reactions of the blood system:the incidence of leukopenia,neutropenia and thrombopenia in the experimental group was lower than that in the control group,and the incidence of 3-4 adverse reactions in the experimental group was lower than that in the control group.The incidence of thrombocytopenia was low in both groups and there was no statistical difference.Non-hematological adverse reactions:patients in two groups mainly present grade 1-2 non-hematological adverse reactions,and there was no statistical difference in gastrointestinal adverse reactions,sensory neuropathy,hepatic injury,infection and fatigue.Conclusion:Two scheme of Nab-Paclitaxel combined with cisplatin in treatment NSCLC with negative driver gene,objective response rate and progression-free survival（PFS）have not significantly difference,but in adverse reactions,the incidence of adverse reactions in the blood system of the experimental group was lower than that of the control group,especially the 3-4 group of adverse reactions,which has guiding significance for the selection of clinical treatment plan.